The role of iron in non-erythroid hematopoietic lineages and its implication in hemato-
oncogenesis are still debated. Iron exerts an important role on hematopoietic stem cell …

Myelodysplastic syndromes (MDS) with ring sideroblasts are hematopoietic stem cell
disorders with erythroid dysplasia and mutations in the SF3B1 splicing factor gene. Patients …

The myelodysplastic syndromes (MDSs) are a heterogeneous group of hematologic
neoplasms with varied natural histories and prognoses. Specific to this review, treatment of …

In low-risk myelodysplastic syndrome (LR-MDS), erythropoietin (EPO) is widely used for the
treatment of chronic anemia. However, initial response to EPO has time-limited effects …

Abstract Background The Molecular International Prognostic Scoring System (IPSS‐M) is the
new gold standard for diagnostic outcome prediction in patients with myelodysplastic …

Ineffective erythropoiesis and iron overload are common in myelodysplastic syndromes
(MDS). Erythroferrone (ERFE) and growth/differentiation factor 15 (GDF15) are two …

Erythropoiesis-stimulating agents (ESAs) are the first-line treatment option for anemia in
patients with lower-risk myelodysplastic syndromes (LR-MDS). A systematic literature review …

Serum ferritin, a marker of systemic iron status, is considered a prognostic factor for patients
with myelodysplastic syndromes (MDS), despite the lack of supporting evidence. We …

Introduction The diagnosis of myelodysplastic syndrome (MDS) is complex. Flow cytometric
analysis of the myelomonocytic compartment can be helpful, but it is highly subjective and …

Myelodysplastic syndromes (MDSs) are a group of hematologic neoplasms accompanied by
dysplasia of bone marrow (BM) hematopoietic cells with cytopenia. Recently, digitalized …